Company: ZDAN
Filing Date: 2025-01-10
Form Type: DRS/A
Source: 0001683168-25-000168
Chunk: 126

Company: Zerolimit Technology Holding Co. Ltd.
Filing Date: 2025-01-10
Form: DRS/A
Chunk 126
---
 to events or information as of the date on which the statements are made
in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the
occurrence of unanticipated events. You should thoroughly read this prospectus and the documents that we refer to herein with the understanding
that our actual future results may be materially different from and worse than what we expect. We qualify all of our forward-looking
statements by these cautionary statements. We disclaim any obligation to update our forward-looking statements, except as required by
law.

Industry Data and Forecasts

This prospectus contains
data related to the VIE’s industry and market position in China and globally. This industry data includes projections that are
based on a number of assumptions which have been derived from industry and government sources which we believe to be reasonable. The
decentralized distributed technology industry may not grow at the rate projected by industry data, or at all. The failure of the industry
to grow as anticipated is likely to have a material adverse effect on the VIE’s business and, accordingly, the market price of
our Ordinary Shares. In addition, the rapidly changing nature of the decentralized distributed technology industry subjects any projections
or estimates relating to the growth prospects or future condition of the VIE’s operations to significant uncertainties. Furthermore,
if any one or more of the assumptions underlying the industry data turns out to be incorrect, actual results may, and are likely to,
differ from the projections based on these assumptions.

| 68 |

<div align='center'>USE OF PROCEEDS</div>

We estimate that we will
receive net proceeds from this offering of approximately US$[*] million, or approximately US$[*] million if the Underwriter exercises
its over-allotment option in full, after deducting underwriting discounts, non-accountable expense allowance and estimated offering expenses
payable by us. These estimates are based upon an assumed initial public offering price of US$[ ] per Ordinary Share.

We plan to use the net proceeds
of this offering (assuming no exercise of the over-allotment option) as follows in the order of priority:

| · | approximately 40%, or US$[*] million for research and development;         |
| · | approximately 25%, or US$[*] million for new product production;           |
| · |